Abu Dhabi Uses AI to Explore New Blood Cancer Treatments

 

How Abu Dhabi Is Using AI to Search for New Blood Cancer Treatments

Scientists examine computer-generated molecular structures as AI-assisted tools help researchers identify and optimize potential drug candidates.

 

Artificial intelligence is increasingly moving beyond chatbots and automation and into one of the world's most difficult scientific challenges: discovering new medicines. In Abu Dhabi, researchers at Insilico Medicine are using generative AI to help identify and design potential drug candidates for blood cancers, marking another step in the UAE's growing ambitions in biotechnology and advanced scientific research. Insilico Medicine's official announcement

The research focuses on BTK-targeting PROTACs, a class of molecules designed to eliminate specific proteins inside cells rather than simply blocking their activity. BTK, or Bruton's tyrosine kinase, is an important protein involved in B-cell signaling and has been studied as a therapeutic target in several blood cancers. The compounds developed by Insilico's Abu Dhabi team are still research-stage candidates, meaning they are not approved cancer medicines and require substantial additional testing before their safety and effectiveness in humans can be established. The National's report on the Abu Dhabi research

Where Artificial Intelligence Enters the Drug Discovery Process

Traditional drug discovery can require years of experimentation before researchers identify a molecule worth developing. Generative AI offers another approach by allowing scientists to analyze biological information and generate potential molecular structures much faster. Insilico says its Chemistry42 platform helped its UAE team design new molecular components and optimize compounds for characteristics including potency, selectivity, toxicity and pharmacokinetic behavior. Insilico Medicine's Chemistry42 and drug-discovery platform

For the blood-cancer research, the team evaluated more than 40 compounds after using AI-supported molecular design. Two lead compounds, ISM-PR25 and ISM-PR44, emerged from the research. According to Insilico, the compounds demonstrated very potent BTK degradation in malignant B cells and showed oral bioavailability in mouse studies. These findings provide a basis for further research, but they should not be confused with evidence that an effective human treatment has already been developed. Insilico Medicine's research announcement

Why the UAE Is Paying Attention

The development is significant not only because of the potential medical application but also because it illustrates the UAE's effort to establish itself as a center for advanced scientific research. Insilico operates an AI and research presence in Abu Dhabi's Masdar City, while local institutions have supported the development of the country's emerging biotechnology ecosystem. Insilico Medicine's Abu Dhabi presence

This is part of a wider progression. Earlier in 2026, the Emirates Drug Establishment announced what it described as the UAE's first fully AI-discovered and developed drug candidate, ISM0387, another Insilico program conducted through its UAE research operations. The candidate targets PRMT5 and is being investigated for cancer applications, demonstrating that the country's AI ambitions are increasingly connected to actual pharmaceutical research rather than remaining purely theoretical. Emirates News Agency report on ISM0387

From AI Discovery to an Actual Medicine

The most important point is that AI can accelerate drug discovery, but it cannot eliminate the scientific process required to prove that a medicine is safe and effective. A promising molecule must go through additional laboratory testing, animal studies and, if it meets the necessary requirements, carefully controlled human clinical trials before regulators can consider approval.

That distinction matters in the case of the Abu Dhabi blood-cancer research. The current findings represent potential drug leads, not a finished therapy. Insilico itself describes ISM-PR25 and ISM-PR44 as research-stage compounds requiring further preclinical and clinical investigation. Insilico Medicine's official research update

A Growing Role for AI in Healthcare

The Abu Dhabi research nevertheless illustrates why pharmaceutical companies are investing heavily in artificial intelligence. AI can help researchers search enormous biological and chemical datasets, identify promising disease targets and generate molecular structures that might otherwise take much longer to discover through conventional approaches. Insilico's broader platform combines AI across biology, chemistry and clinical development, with the stated goal of reducing the time and cost associated with bringing medicines to patients. Insilico Medicine's AI drug-discovery platform

For the UAE, the development also represents a broader investment in scientific capability. Building local teams capable of combining computational science, medicinal chemistry and experimental biology could allow the country to participate more directly in global pharmaceutical innovation. Abu Dhabi's blood-cancer research is therefore worth watching—not because AI has already produced a new cancer cure, but because it shows how quickly the relationship between artificial intelligence and medicine is evolving. The National's coverage of the UAE research ecosystem




Comments

Popular posts from this blog

Five Kenyan Security Officers Killed in Al-Shabaab IED Attack Near Somalia Border

Filling the Gap: Ukraine Turns to African Labor to Combat Historic Workforce Shortage

UAE’s ‘Invest in the Emirates’ campaign to attract world’s top innovators, talents and entrepreneurs